Aspaveli® (pegcetacoplan), based on technology developed by John Lambris, PhD, the Dr. Ralph and Sallie Weaver Professor of Research Medicine at Penn Medicine, received expanded approval from the European Commission for its use in the treatment of primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) and C3 glomerulopathy (C3G). Aspaveli ® is also approved for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH) in the United States, European Union, and other countries globally. Learn more here.